vidarabine has been researched along with Leukemia, Prolymphocytic, B-Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Sharkawi, D; Stewart, A; Williams, R | 1 |
| Fahrmann, JF; Hardman, WE | 1 |
| Berthou, C; Dalbies, F; De Braekeleer, M; Feuerbach, J; Ianotto, JC; Le Bris, MJ; Marion, V; Tempescul, A | 1 |
| Batár, P; Rejto, L; Telek, B; Udvardy, M | 1 |
4 other study(ies) available for vidarabine and Leukemia, Prolymphocytic, B-Cell
| Article | Year |
|---|---|
Systemic capillary leak syndrome: a rare but potentially life-threatening cause of protein loss and oedema in B cell prolymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Cyclophosphamide; Edema; Humans; Hypoalbuminemia; Leukemia, Prolymphocytic, B-Cell; Male; Middle Aged; Rituximab; Serum Albumin, Human; Treatment Outcome; Vidarabine | 2020 |
Omega 3 fatty acids increase the chemo-sensitivity of B-CLL-derived cell lines EHEB and MEC-2 and of B-PLL-derived cell line JVM-2 to anti-cancer drugs doxorubicin, vincristine and fludarabine.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Arachidonic Acid; Cell Line, Tumor; Docosahexaenoic Acids; Doxorubicin; Drug Resistance, Neoplasm; Eicosapentaenoic Acid; G2 Phase Cell Cycle Checkpoints; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic, B-Cell; Lipid Peroxidation; Malondialdehyde; Organ Specificity; Reactive Oxygen Species; Vidarabine; Vincristine; Vitamin E | 2013 |
A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Prolymphocytic, B-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Rituximab; Vidarabine | 2009 |
[Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Humans; Immunophenotyping; Leukemia, Prolymphocytic, B-Cell; Male; Prognosis; Rituximab; Treatment Outcome; Vidarabine | 2010 |